MEDICAL PRACTICE

Consensus in Medicine
The consensus development programme: technology assessment at the National Institute of Health CHARLES U LOWE Are there some medical technologies in general use that are unsafe or ineffective ? Are there still other drugs, devices, and medical or surgical procedures that have not been widely accepted even though well validated? These are the kinds of questions, raised in recent years, that have led to a reassessment of the process by which technologies are transferred from research and development into practice.
During the past 30 years major advancements have been made in medical care, and with these improvements has come a rapid expansion of the role of science and technology in medicine. In the United States, however, there was no formal mechanism within the biomedical research community to ensure that findings were systematically identified and evaluated to determine whether they were suitable for introduction into practice.
Consensus conferences
Amid a growing public concern about the lack of a more organised system of assessing medical technologies, the National Institutes of Health in 1977 initiated its Consensus Development Programme. The purpose was to help improve the translation of the results of biomedical research into knowledge that could be used effectively in the practice of medicine and public health.
A key element in the programme is the consensus conference, which brings together scientists, practitioners, consumers, and others in an effort to reach general agreement on the safety and efficacy of medical technologies. The technologies may be emerging or may be in general use. They may be drugs, devices, or medical, surgical, or dental procedures.
The Consensus Development Programme is aimed at complementing-but not replacing-the usual means of reporting research results through publication in scientific journals and other medical periodicals and through the lay press. The primary objective of the programme is to provide the physician and the public with the most accurate, current information about the benefits and risks of complex, often controversial, medical technologies.
Consensus development conferences differ from standard scientific state-of-the-art meetings in that consensus panels must consider specific sets of questions. After listening to a series of expert presentations, these panels are then asked to issue a set of recommendations framed around the original questions and directed to the technology under discussion.
The value of the reports prepared by consensus panel members is that they may identify safe and useful new medical technologies and make a wider audience aware of their availability. On other occasions they may point out some potential problems which could result from the use of an existing technology. In some cases panels may even recommend against using a medical or surgical procedure, device, or drug under certain conditions. Sometimes the consensus indicates that a technology has not been adequately validated.
The best current thinking Whatever the conclusions drawn by a panel, the group's report is offered as an aid to the physician and the public. The hope is that the more current, reliable scientific information reaches the medical profession and the public the more the quality of health care will improve. Another important feature of consensus development conferences is the inclusion of ample time on the agenda for public comments. Frequently, the consensus report reflects some key points made by knowledgeable members of the audience.
It is desirable that panel lists explore all sides of a question, and panel members who disagree with major conclusions are encouraged to develop a minority report.
The fact that panel members may be unable to reach consensus on a specific point may sometimes be as valuable as when they are in agreement because this could well point to a need to develop more data on the subject in question.
So far the NIH Consensus Development Programme has conducted some two dozen conferences on a wide range of subjects (see table) . 
